**Core tip:** Celiac disease (CD) is more common in children with Down syndrome (DS) than in general population. Recommendations for screening for DS and CD remain controversial and we still lack standard evidence-based guidelines. This review, based on existing reports, indicates the need for establishing uniform and immediately applicable diagnostic criteria.

INTRODUCTION
============

Down syndrome (DS) is a chromosomal disorder caused by trisomy and other aberrations of chromosome 21\[[@B1]\]. This syndrome was first described by Langdon Down\[[@B2]\] in 1886, while in 1959, French pediatrician and geneticist. Lejeune published a paper in which he identified trisomy 21 as its genetic cause\[[@B3]\]. It occurs with a prevalence of 1:733, therefore representing the most common chromosomal disorder and one of the leading causes of mental retardation\[[@B4]\]. DS is characterized by many typical somatic and visceral malformations. People with this syndrome are prone to autoimmune and other diseases, such as hearing and vision problems, immune dysfunction, obstructive sleep apnea, Alzheimer disease-like dementia, megakaryoblastic leukemia, hypothyroidism, diabetes mellitus (DM), and celiac disease (CD)\[[@B1],[@B4]\].

CD is an autoimmune disorder induced by gluten-containing food from seeds of wheat, rye, and barley\[[@B5]\]. It can develop at any age as a result of an inherited (polygenic) disposition and exposure to gluten. Research carried out during the last two decades has shown that a central role in the occurrence of the disease is played by MHC class II HLA antigens: HLA-DQ2 and HLA-DQ8\[[@B6]\]. The absence of HLA-DQ2 and HLA-DQ8 has a strong negative predictive value for CD\[[@B7]\]. Therefore, the question remains, why only a small percent of patients develops CD while approximately 40% of the population carries HLA-DQ2/DQ8 alleles and is exposed to gluten without developing a disease.

Even though enteropathy is the primary characteristic of the disease, CD may involve other extraintestinal organs\[[@B8]\]. Based on clinical, serological and histological variations, CD may be classified into two basic types: symptomatic and asymptomatic. Within symptomatic form of the disease, there are forms with classical and atypical clinical picture\[[@B9]\]. Classical form of CD occurs in infants and toddlers (9-36 mo) and it is characterized by gradual, rarely sudden onset of the disease. It is presented with a chronic diarrheal disorder, anorexia, vomiting, abdominal distension and pain, and in the most severe cases, with celiac crisis\[[@B10]\]. In the past two decades, the classical clinical manifestations in patients became less common, and we can see the emergence of a growing number of cases with the atypical form of CD (1:8 in general population)\[[@B11]\]. Among adolescents and adults, disease presents in atypical form, with absent or mild gastrointestinal symptoms, and with more common extraintestinal manifestations, such as sideropenic anemia resistant to oral therapy with iron, delay in longitudinal growth, marked thinness, chronic fatigue, osteopenia and osteoporosis, enamel hypoplasia, arthralgia, myalgia, epilepsy, ataxia, polyneuropathy, vitiligo, alopecia, dermatitis herpetiformis, *etc*\[[@B12]\].

Autoimmune diseases are ten times more common in patients with CD compared to general population. Such diseases include type 1 DM, autoimmune thyroid disease, Sjögren's syndrome, Addison's disease, chronic active hepatitis (elevated transaminases), primary biliary cirrhosis, IgA nephropathy, and juvenile chronic arthritis. Almost the same prevalence of the disease is also found in some chromosomal aberration disorders, such as Turner syndrome, Williams syndrome, and DS\[[@B13],[@B14]\].

Diagnosis of CD is based on histological analysis of duodenal biopsies, HLA testing for HLA-DQ2 and HLA-DQ8, and detection of specific autoantibodies (mostly immunoglobulin A tissue transglutaminase - anti-TG2 and/or anti-endomysial antibodies - EMA). Gliadin antibody test and IgG class anti-TG2 antibody does not have the same specificity and clinical relevance. Use of a gluten-free diet is an effective treatment for CD as it has been shown to decrease the severity of clinical symptoms and reduce the risk of complications\[[@B6]-[@B8],[@B15]\].

CD AND DS
=========

Association between CD and DS was first described in 1975, by Bentley et al\[[@B16]\]. Since then, many papers were published in Europe, reporting the prevalence of CD in DS patients to be from 0-18.6%\[[@B17]-[@B28]\] (Figure [1](#F1){ref-type="fig"}), which is far more prevalent than CD in general population (1% in Western countries)\[[@B29]\].
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Similar prevalence of CD among DS patients were found in the United States - 3.8% and 10.3%\[[@B30],[@B31]\], Australia 3.9%\[[@B32]\], Argentina - 3.6%\[[@B33]\], and Brazil - 5.6%\[[@B34]\]. The reported rates are probably overestimated because most of the authors did not perform small bowel biopsy in all DS patients with positive serology\[[@B20],[@B23],[@B25]-[@B27],[@B31]-[@B34]\]. Variability in prevalence may have been caused by differences in type of antibody used for screening, different cohort sizes (25-1453), variable age stratification and applied criteria for CD diagnosis. Most of the studies were conducted on patients receiving care from local medical centers, and only a few studies were conducted at the level of the region or a country\[[@B18],[@B20],[@B24],[@B32]\]. Furthermore, in the majority of children, the authors did not perform testing for HLA-DQ2 and HLA-DQ8 recommended by European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) criteria\[[@B15]\].

In their study, Pavlovic et al\[[@B17]\] did not find CD in any of 82 children with DS. This can be explained by age of children (8 mo to 8.6 years), but further serological monitoring of these children would probably show the presence of the disease in this group of patients. Higher prevalence was found only in two previous smaller series from Sweden; Jansson and Johansson\[[@B23]\] screened 65 DS patients and they found CD prevalence of 16.9% while Carlsson et al\[[@B24]\] reported the similar prevalence of 18.6% (8/43). These regional differences raise the question about the relationship of environmental factors and ethnic influence.

Compared to the general population, the symptomatic form of CD is more frequent in DS children than asymptomatic form\[[@B35]\]. However, about one-third of DS patients with CD have no gastrointestinal symptoms\[[@B20]\]. In children with DS and symptomatic form of CD, growth failure, anemia, intermittent diarrhea, vomiting, and constipation are described as the most common manifestations of the disease\[[@B36]\]. Their significance in clinical practice is not entirely obvious, bearing in mind the occurrence of the same symptoms and signs in children with DS, but without CD. Because of intellectual disability, DS patients may also be unable to accurately describe their symptoms. Growth failure as the manifestation of CD has little significance in children with DS, considering that the associated malformations, such as congenital heart defects and hypothyroidism, may also have the same effect\[[@B37]\]. Late identification or missed diagnosis of CD in DS patients can lead to failure to thrive, anemia, osteoporosis, and lymphoma\[[@B14],[@B15]\].

WHEN AND HOW SHOULD WE SCREEN?
==============================

The screening is planned on the basis of prevalence of the disease, sensitivity and specificity of tests, complications or comorbidities of the disease, effectiveness of the therapy (gluten-free diet), and costs. Swigonski et al\[[@B38]\] believe that the consistent use of serological screening for CD might not be entirely justified, primarily for economic reasons. Kolek et al\[[@B19]\] suggest CD screening only in patients with symptoms (loose stool, constipation, abdominal discomfort), but not in patients without symptoms. Mackey et al\[[@B39]\] suggested routine follow-up testing at least every 3 years for all children with DS, and yearly CD screening for patients who are serology positive and biopsy-negative.

Despite some common diseases associated with DS have clear screening guidelines, *e.g*., thyroid function, screening for CD remains controversial still lacking standard evidence-based guidelines (Table [1](#T1){ref-type="table"}).

###### 

Health care guidelines for people with Down syndrome

  **Association**                                                                             **Screening for other diseases**                  **CD screening**             **CD antibodies**                     **Further CD antibodies testing**                 **HLA testing**
  ------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------- ------------------------------------- ------------------------------------------------- -----------------------------
  United Kingdom Down's Syndrome Medical Interest Group\[[@B41]\]                             Thyroid function                                  No                           No                                    No                                                No
  American Academy of Pediatrics\[[@B42]\]                                                    Thyroid function, anemia                          Symptomatic patients         IgA, IgA anti-TG2                     No                                                No
  American Family Physician\[[@B43]\]                                                         Thyroid function, diabetes mellitus               Not for adult                No                                    No                                                No
  American Gastroenterological Association\[[@B44]\]                                                                                            Symptomatic patients         IgA anti-TG2, IgA EMA                 No                                                If other tests is not clear
  National Institute for Health and Care Excellence\[[@B45]\]                                                                                   In all patients              IgA anti-TG2                          No                                                No
  European Down Syndrome Association\[[@B46]\]                                                Thyroid function, anemia, immunological defects   In all patients              IgG, IgA AGA, IgA anti-TG2, IgA EMA   Annually                                          No
  Down's Syndrome Medical Interest Group\[[@B47]\]                                            Thyroid function                                  At 2-3 yr in all patients    IgA EMA                               No                                                No
  North American Society for Pediatric Gastroenterology, Hepatology and Nutrition\[[@B48]\]                                                     After 3 yr in all patients   IgA, IgA anti-TG2                     Some years                                        If IgA anti-TG2 negative
  European Society for Pediatric Gastroenterology, Hepatology and Nutrition\[[@B15]\]                                                           After 2 yr in all patients   IgA anti-TG2 if HLA positive          Every 2 to 3 yr in DQ2 or DQ8 positive children   Yes

CD: Celiac disease; EMA: Antiendomisium antibodies; AGA: Antigliadin antibodies; anti-TG2: Tissue transglutaminase antibodies; IgA: Immunoglobulin A; IgG: Immunoglobulin G.

The healthcare guidelines for patients with DS developed by the American Academy of Pediatrics (AAP)\[[@B40]\] published in 2001 and Down's Syndrome Medical Interest Group United Kingdom and Ireland\[[@B41]\] did not made any recommendations for CD screening, even though they advised thyroid screening tests annually (risk of thyroid disease is 15%). Ten years later, AAP changed its position and advised screening for CD in the presence of symptoms, such as protracted constipation, slow growth, unexplained failure to thrive and anemia\[[@B42]\]. American Gastroenterological Association suggested that antibodies testing for CD is justified in patients with symptoms, but not those without symptoms and that HLA testing is appropriate only when the diagnosis based on other tests is not clear\[[@B44]\]. The recent recommendations by National Institute for Health and Care Excellence consider serological testing for CD in DS patients with IgA anti-TG2 as the first line of screening, and IgA EMA only if IgA anti-TG2 is weakly positive\[[@B45]\]. These recommendations do not imply HLA testing in the initial diagnosis of CD. The European Down Syndrome Association recommends blood tests for anemia, thyroid disease, CD and autoimmune disorders at 12 mo, and yearly thereafter, until old age in all patients\[[@B46]\]. The Down's Syndrome Medical Interest group\[[@B47]\] recommends lifetime annual thyroid screening, and one-time screening for CD between ages 2 and 3, although North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) reports that the youngest child with both DS and CD diagnosed through screening was 3.2 years old. On the other hand, NASPGHAN has suggested that CD screening of children with DS once in a lifetime is not enough and that periodic screening should be done\[[@B48]\]. Finally, according to the latest recommendations of the ESPGHAN from 2012, human leukocyte antigen HLA-DQ2 and HLA-DQ8 typing should be the first line of screening\[[@B15]\]. In patients who are HLA-DQ2 and HLA-DQ8 negative, further serological testing is unnecessary. If the patient is DQ8 and/or DQ2 positive, then an anti-TG2 IgA test and total IgA determination should be performed. If antibodies are negative, repeated testing for CD-specific antibodies is recommended every 2 to 3 years. Although HLA typing is relatively expensive and not always feasible, finally, it likely seems to be a cost-effective procedure because the significant proportion of patients can be excluded from further antibodies testing.

CONCLUSION
==========

DS patients have increased the risk of congenital malformations and a higher incidence of CD. Current evidence has important implications to support obligatory screening for CD in DS patients. Currently, many policy statements vary in their recommendations, and there is a need for further harmonization. The strategy should aim at early diagnosis and treatment of the condition in order to prevent the development of osteoporosis and lymphoma, as the most severe complication of this disease.
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